Drug intelligence / Profile preview

ENL210

Development stage: Preclinical
Lead developer: Enlyton
Modality: scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ENL210 is a bioengineered monoclonal antibody fragment being developed by Enlyton as a targeted imaging and therapeutic agent for a broad range of solid tumors that express tumor-associated glycoprotein 72 (TAG-72). It is designed to selectively bind TAG-72, a cell-surface glycoprotein overexpressed in many epithelial cancers, enabling intraoperative and preoperative molecular imaging and potentially delivering tumor-specific therapy while sparing normal tissues.[1][3][11][15]

Targets

TAG-72

Beyond the preview

Go deeper on ENL210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENL210.

Explore the full profile